Tolvaptan and hyponatremia in a patient with cirrhosis

Hepatology

Volumn 51, Issue 2, 2010, Pages 699-702

  Boyer, Thomas D ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; SAMSCA; SPIRONOLACTONE; TOLVAPTAN; UNCLASSIFIED DRUG;

ADULT; ALCOHOL LIVER CIRRHOSIS; ANOREXIA; ARTICLE; ASCITES; ASTHENIA; CASE REPORT; CONSTIPATION; DRUG FEVER; DYSPNEA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; MALE; POLYURIA; PRIORITY JOURNAL; SIDE EFFECT; THIRST; XEROSTOMIA;

BENZAZEPINES; HUMANS; HYPONATREMIA; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN;

EID: 75449096142     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23522     Document Type: Article

References (13)

1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157.
2. Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998;28:851-864.
3. Angeli P, Wong F, Watson H, Gines P, and the CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006;44:1535-1542.
4. Heuman DM, Abou-assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at risk for early death. Hepatology 2004;40:802-810.
5. Biggins SW, Rodriquez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. HEPATOLOGY 2005;41:32-39.
6. Londono MC, Guevara M, Rimola A, Navasa M, Taura P, Mas A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006;130:1135-1143
7. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized placebo-controlled trial. Hepatology 2003;37:182-191.
8. Gines P, Cardenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008;28:43-58.
9. Kumar S, Berl T. Vasopressin antagonists in the treatment of water-retaining disorders. Semin Nephrology 2008;28:279-288.
10. Gines P, Wong F, Watson H, Milutinovic S, del Arbo LR, Olteanu D, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. Hepatology 2008;48:204-213.
11. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112.
12. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022275s000TOC.cfm
13. Wong F, Gines P, Nevens F, Van Vlierberghe H, Gerbes A, Zarski J-P, et al. Double-blind placebo-controlled study of satavaptan in the management of recurrent ascites [Abstract]. HEPATOLOGY 2009;50(Suppl):448A.